411 related articles for article (PubMed ID: 31566666)
1. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
4. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Yamada I; Morizane C; Okusaka T; Mizusawa J; Kataoka T; Ueno M; Ikeda M; Okano N; Todaka A; Shimizu S; Mizuno N; Sekimoto M; Tobimatsu K; Yamaguchi H; Nishina T; Shirakawa H; Kojima Y; Oono T; Kawamoto Y; Furukawa M; Iwai T; Sudo K; Okamura K; Yamashita T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Sci Rep; 2022 Jan; 12(1):987. PubMed ID: 35046457
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
Morizane C; Okusaka T; Mizusawa J; Takashima A; Ueno M; Ikeda M; Hamamoto Y; Ishii H; Boku N; Furuse J
Cancer Sci; 2013 Sep; 104(9):1211-6. PubMed ID: 23763511
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
[TBL] [Abstract][Full Text] [Related]
8. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
[No Abstract] [Full Text] [Related]
13. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
14. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
